Lymphoma News and Research

RSS
Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.
RESILIENCE project aims to reduce the burden of cardiovascular disease in cancer survivors

RESILIENCE project aims to reduce the burden of cardiovascular disease in cancer survivors

FDA approves alternative component of chemotherapy regimen to treat acute lymphoblastic leukemia

FDA approves alternative component of chemotherapy regimen to treat acute lymphoblastic leukemia

Maternal Omega 3-rich diet may reduce onset of breast cancer in offspring

Maternal Omega 3-rich diet may reduce onset of breast cancer in offspring

New blood test can accurately detect 50 types of cancer before symptoms emerge

New blood test can accurately detect 50 types of cancer before symptoms emerge

Researchers discover new class of drugs that inhibits a 'master switch' in mantle cell lymphoma

Researchers discover new class of drugs that inhibits a 'master switch' in mantle cell lymphoma

Smoother silicone breast implants can reduce inflammation and other immune system reactions

Smoother silicone breast implants can reduce inflammation and other immune system reactions

Researchers analyze how breast implant surfaces influence immune response

Researchers analyze how breast implant surfaces influence immune response

New breakthrough could lead to a cure for common childhood cancer

New breakthrough could lead to a cure for common childhood cancer

New research uncovers substantial differences in rates of childhood cancers

New research uncovers substantial differences in rates of childhood cancers

Convalescent plasma associated with better survival in blood cancer patients with COVID-19

Convalescent plasma associated with better survival in blood cancer patients with COVID-19

Convalescent plasma can improve chances of survival among blood cancer patients with COVID-19

Convalescent plasma can improve chances of survival among blood cancer patients with COVID-19

Foresight Diagnostics to demonstrate utility of PhasED-Seq technology at ICML meeting

Foresight Diagnostics to demonstrate utility of PhasED-Seq technology at ICML meeting

UC San Diego Health offers new immunotherapy treatment for multiple myeloma following FDA approval

UC San Diego Health offers new immunotherapy treatment for multiple myeloma following FDA approval

Urgent action needed to address the shortage of hematologists in Africa, experts say

Urgent action needed to address the shortage of hematologists in Africa, experts say

Aptamer Group and PinotBio collaborate to develop new therapeutic drug conjugates

Aptamer Group and PinotBio collaborate to develop new therapeutic drug conjugates

Moffitt Cancer Center presents new data from dozens of clinical research studies at ASCO

Moffitt Cancer Center presents new data from dozens of clinical research studies at ASCO

Higher CD8 T cells may influence COVID-19 recovery in blood cancer patients

Higher CD8 T cells may influence COVID-19 recovery in blood cancer patients

Extensive cancer research data to be presented at the 2021 ASCO Annual Meeting

Extensive cancer research data to be presented at the 2021 ASCO Annual Meeting

‘Kicking you when you’re down’: Many cancer patients pay dearly for parking

‘Kicking you when you’re down’: Many cancer patients pay dearly for parking

NK cells combined with bispecific antibody display potent anti-tumor activity against lymphoma cells

NK cells combined with bispecific antibody display potent anti-tumor activity against lymphoma cells

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.